 |
 |
 |
 |
 |
 |
 |
|
|
|
|||||||||
|
|||||||||||
Clinical Pharmacist, Pharmacy Department, Alicante University General Hospital, Alicante, Spain
Clinical Pharmacist, Pharmacy Department, Alicante University General Hospital
Clinical Specialist, Pharmacy Department, Alicante University General Hospital
Clinical Specialist, Pharmacy Department, Alicante University General Hospital
Clinical Specialist; Director, Department of Pharmacy, Alicante University General Hospital
Reprints: Carmen Hernández Prats PharmD, Hospital General de Alicante, Servicio de Farmacia, Maestro Alonso n° 109, CP 03010 Alicante, España, fax 965938908, fgtorregrosa{at}terra.es
OBJECTIVE: To describe the first case, to the best of our knowledge, of posttraumatic Scedosporium apiospermum (ScA) keratitis successfully treated with systemic and topical voriconazole.
CASE SUMMARY: A 19-year-old man was admitted to the hospital with an incisive wound of his left eye and the cornea totally sectioned after trauma with a cutter used in gardening. Initial empirical treatment was followed by systemic and topical voriconazole, and the eye did not have to be enucleated. Five months after the trauma, a penetrating keratoplasty and chamber intraocular lens implantation was performed with a favorable visual outcome.
DISCUSSION: ScA keratitis is rare, but it must be suspected if a history of ocular injury with contaminated objects exists. Among the antifungals available to treat ScA keratitis, voriconazole has shown advantages such as the lowest minimum inhibitory concentration and the availability of an oral formulation.
CONCLUSIONS: Voriconazole shows promise as an effective alternative to conventional antifungals in the treatment of ScA keratitis. It is available both as oral and intravenous preparations, which is a great advantage in these lengthy infections.
Key Words: fungal keratitis, Scedosporium apiospermum, voriconazole
Published Online, January 30, 2004. www.theannals.com, DOI 10.1345/aph.1D128
This article has been cited by other articles:
|
|
 |
|
  S M Hariprasad, W F Mieler, T K Lin, W E Sponsel, and J R Graybill Voriconazole in the treatment of fungal eye infections: a review of current literature Br. J. Ophthalmol., July 1, 2008; 92(7): 871 - 878. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Lau, M. Fedinands, L. Leung, R. Fullinfaw, D. Kong, G. Davies, and M. Daniell Penetration of Voriconazole, 1%, Eyedrops Into Human Aqueous Humor: A Prospective Open-Label Study Arch Ophthalmol, March 1, 2008; 126(3): 343 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Cortez, E. Roilides, F. Quiroz-Telles, J. Meletiadis, C. Antachopoulos, T. Knudsen, W. Buchanan, J. Milanovich, D. A. Sutton, A. Fothergill, et al. Infections Caused by Scedosporium spp. Clin. Microbiol. Rev., January 1, 2008; 21(1): 157 - 197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Lalitha, B. L. Shapiro, M. Srinivasan, N. V. Prajna, N. R. Acharya, A. W. Fothergill, J. Ruiz, J. D. Chidambaram, K. J. Maxey, K. C. Hong, et al. Antimicrobial Susceptibility of Fusarium, Aspergillus, and Other Filamentous Fungi Isolated From Keratitis Arch Ophthalmol, June 1, 2007; 125(6): 789 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Thiel, A. S. Zinkernagel, J. Burhenne, C. Kaufmann, and W. E. Haefeli Voriconazole Concentration in Human Aqueous Humor and Plasma during Topical or Combined Topical and Systemic Administration for Fungal Keratitis Antimicrob. Agents Chemother., January 1, 2007; 51(1): 239 - 244. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. C. Klein and R. A. Blackwood Topical Voriconazole Solution for Cutaneous Aspergillosis in a Pediatric Patient After Bone Marrow Transplant Pediatrics, August 1, 2006; 118(2): e506 - e508. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
 |
 |
 |
 |
